Business Standard

Sun Pharma at new high on FDA nod for generic version of Januvia

USFDA has granted its subsidiary, two tentative approvals for its ANDA for generic version of Januvia, Sitagliptin tablets and generic version of Glumetza, Metformin HCl extended-release tablets.

Related News

Sun Pharmaceutical Industries has moved higher by 3% to Rs 914, extending its previous day’s 2.3% gain after the company said it has received a tentative approval from the US drug regulator for generic version of Januvia.

The stock opened at Rs 886 and hit a new high of Rs 920 on NSE. The trading volumes on the counter more than doubled with a  combined 699,849 shares changing hands till 1141 hours on NSE and BSE.

On Monday, said that the US Food and Drugs Administration (USFDA) has granted its subsidiary, two tentative approvals for its Abbreviated New Drug Applications (ANDA) for generic version of Januvia, Sitagliptin tablets and generic version of Glumetza, Metformin HCl extended-release tablets.

Sitagliptin tablets have annual sales of approximately US$ 2.7 billion, while Metformin HCl Extended-release tablets have annual sales of approximately US$ 140 million in the US, it added.

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus. Metformin HCl Extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus.
 

Read more on:   
|
|

Read More

Fresenius Kabi Oncology soars on delisting plan

The promoter intends to pay an indicative price of Rs 130 per share to acquire the shares offered to it in the Delisting Offer

Quick Links

 

Market News

Markets flat; Technology stocks surge

The 30-share Sensex is down 40 points at 26,590 and 50-share Nifty has lost 13 points at 7,952.

Videocon Industries gains as subsidiary considers IPO

Videocon Industries has gained 2.5% on BSE on the reports about Videocon d2h considering a pre-IPO placement

Copper softens on weak global cues

Subdued demand at domestic spot markets also weighed on metal prices

Gold futures fall 0.6% on weak global cues

Speculators indulged in reducing exposures amid a weak global trend

Silver futures decline 1.1% on global cues

Speculators trimmed positions amid weak cues from global markets

Back to Top